You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 139 No. 7, July 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (37)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Dermatologic Disorders, Other
 •Alert me on articles by topic

What Nephrogenic Fibrosing Dermopathy Might Be

Arch Dermatol. 2003;139:928-930.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MOST "NEW" diseases are the product of humans intervention. New drug reactions, diseases in transplant recipients, and even new epidemics (eg, human immunodeficiency virus disease) have been brought about or facilitated by changes in human behavior. The condition currently called nephrogenic fibrosing dermopathy (NFD) will likely be an example of such a condition, but the proof is not in yet.

In 1997, nephrologists at a medical center in southern California began seeing patients who had extensive cutaneous induration. Most of these patients were recipients of renal transplants, and in many cases the transplants had been rejected. Biopsy results of several of these patients led to the conclusion that they all had the same condition, one that resembled or perhaps was scleromyxedema. From the outset, it was clear that the condition was distinct from morphea or scleroderma.

Shortly thereafter, the pathologists who saw these cases sent me sections of the biopsy . . . [Full Text of this Article]


RELATED ARTICLE

Nephrogenic Fibrosing Dermopathy With Systemic Involvement
William W. Ting, Mary Seabury Stone, Kathi C. Madison, and Kevin Kurtz
Arch Dermatol. 2003;139(7):903-906.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Acute phase reaction to gadolinium-DTPA in dialysis patients
Steen et al.
Nephrol Dial Transplant 2008;0:gfn655v1-gfn655.
ABSTRACT | FULL TEXT  

Nephrogenic Systemic Fibrosis: A Report of 29 Cases
Shabana et al.
Am. J. Roentgenol. 2008;190:736-741.
ABSTRACT | FULL TEXT  

Nephrogenic Systemic Fibrosis: A Population Study Examining the Relationship of Disease Development to Gadolinium Exposure
Deo et al.
CJASN 2007;2:264-267.
ABSTRACT | FULL TEXT  

Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should Be Concerned
Broome et al.
Am. J. Roentgenol. 2007;188:586-592.
ABSTRACT | FULL TEXT  

Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy.
Swaminathan et al.
ANN INTERN MED 2006;145:234-235.
FULL TEXT  

Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?
Grobner
Nephrol Dial Transplant 2006;21:1104-1108.
FULL TEXT  

Case 35-2004 - A 68-Year-Old Man with End-Stage Renal Disease and Thickening of the Skin
Moschella et al.
NEJM 2004;351:2219-2227.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.